Page last updated: 2024-10-26

fenfluramine and Cardiovascular Diseases

fenfluramine has been researched along with Cardiovascular Diseases in 14 studies

Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"The results of this study support the longer term use of dexfenfluramine therapy for patients with chronic obesity."9.08Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. ( Caterson, ID; O'Connor, HT; Richman, RM; Steinbeck, KS, 1995)
"Dexfenfluramine lowers body weight in obese patients with upper and lower body obesity and reduces the cardiovascular risk factors clustering in upper body obesity."9.08The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996)
"The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additional group therapy."9.07Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. ( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994)
"Dexfenfluramine- and placebo-treated patients achieved a similar weight loss (greater than 10% of initial weight, by 39."6.67Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. ( Kok, AM; Mathus-Vliegen, EM; Res, AM; van de Voorde, K, 1992)
"The results of this study support the longer term use of dexfenfluramine therapy for patients with chronic obesity."5.08Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. ( Caterson, ID; O'Connor, HT; Richman, RM; Steinbeck, KS, 1995)
"Dexfenfluramine lowers body weight in obese patients with upper and lower body obesity and reduces the cardiovascular risk factors clustering in upper body obesity."5.08The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996)
"The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additional group therapy."5.07Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. ( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994)
" As a derivative of fenfluramine with an appetite suppressant action, benfluorex is preferentially used in overweight patients."3.75Fenfluramine-like cardiovascular side-effects of benfluorex. ( Boutet, K; Carlhant-Kowalski, D; Frachon, I; Gut-Gobert, C; Humbert, M; Jobic, Y; Leroyer, C; Simonneau, G; Sitbon, O, 2009)
"To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk."3.70Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999)
"Dexfenfluramine treatment augments weight and fat loss on a reduced-fat, ad libitum diet, with some evidence for preferential loss of waist fat compared with hip fat."2.68Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. ( Carmichael, HE; Swinburn, BA; Wilson, MR, 1996)
"Dexfenfluramine- and placebo-treated patients achieved a similar weight loss (greater than 10% of initial weight, by 39."2.67Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. ( Kok, AM; Mathus-Vliegen, EM; Res, AM; van de Voorde, K, 1992)
" Receptorome screening has implicated N-deethylation of fenfluramine and serotonin 5-hydroxy-t-ryptamine 2B receptors in the adverse effects of the drug; subsequent studies corroborated this finding."2.43Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. ( Roth, BL; Setola, V, 2005)
"Obesity is a major risk factor for morbidity and mortality, and a series of pharmacologic approaches are available for helping to manage the problem."2.40The pharmacologic approach to the treatment of obesity. ( Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M, 1997)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (71.43)18.2507
2000's4 (28.57)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boutet, K1
Frachon, I1
Jobic, Y1
Gut-Gobert, C1
Leroyer, C1
Carlhant-Kowalski, D1
Sitbon, O1
Simonneau, G1
Humbert, M1
Setola, V1
Roth, BL1
Després, JP1
Lemieux, S1
Lamarche, B1
Prud'homme, D1
Moorjani, S1
Brun, LD1
Gagné, C1
Lupien, PJ1
O'Connor, HT1
Richman, RM1
Steinbeck, KS1
Caterson, ID1
Bremer, JM1
Scott, RS1
Lintott, CJ1
Pfohl, M1
Luft, D1
Blomberg, I1
Schmülling, RM1
Swinburn, BA1
Carmichael, HE1
Wilson, MR1
Ditschuneit, HH1
Flechtner-Mors, M1
Adler, G1
Weiser, M1
Frishman, WH1
Michaelson, MD1
Abdeen, MA1
Greenway, FL1
Ryan, DH1
Bray, GA1
Rood, JC1
Tucker, EW1
Smith, SR1
Curzon, G1
Gibson, EL1
Kilpatrick, IC1
Traut, M1
Heal, DJ1
Mathus-Vliegen, EM1
van de Voorde, K1
Kok, AM1
Res, AM1

Reviews

4 reviews available for fenfluramine and Cardiovascular Diseases

ArticleYear
Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.
    Expert opinion on drug metabolism & toxicology, 2005, Volume: 1, Issue:3

    Topics: Animals; Appetite Depressants; Cardiovascular Diseases; Drug Evaluation, Preclinical; Drug-Related S

2005
The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1995, Volume: 19 Suppl 1

    Topics: Adipose Tissue; Cardiovascular Diseases; Fenfluramine; Humans; Hyperlipidemias; Insulin Resistance;

1995
The pharmacologic approach to the treatment of obesity.
    Journal of clinical pharmacology, 1997, Volume: 37, Issue:6

    Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabo

1997
The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection.
    Advances in experimental medicine and biology, 1999, Volume: 467

    Topics: Appetite; Brain; Cardiovascular Diseases; Fenfluramine; Humans; Phentermine; Selective Serotonin Reu

1999

Trials

6 trials available for fenfluramine and Cardiovascular Diseases

ArticleYear
Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1995, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Anthropometry; Body Composition; Body Constitution; Cardiovascular Diseases; Chol

1995
Dexfenfluramine reduces cardiovascular risk factors.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1994, Volume: 18, Issue:4

    Topics: Apolipoproteins B; Body Mass Index; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Choleste

1994
Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1994, Volume: 18, Issue:6

    Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cardiovascular Diseases; Cholesterol; Female; Fe

1994
Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1996, Volume: 20, Issue:11

    Topics: Adipose Tissue; Adult; Aged; Appetite Depressants; Body Composition; Cardiovascular Diseases; Dietar

1996
The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
    Journal of cardiovascular risk, 1996, Volume: 3, Issue:4

    Topics: Adult; Analysis of Variance; Appetite Depressants; Body Mass Index; Body Weight; Cardiovascular Dise

1996
Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
    Journal of internal medicine, 1992, Volume: 232, Issue:2

    Topics: Adult; Analysis of Variance; Cardiovascular Diseases; Feeding Behavior; Female; Fenfluramine; Humans

1992

Other Studies

4 other studies available for fenfluramine and Cardiovascular Diseases

ArticleYear
Fenfluramine-like cardiovascular side-effects of benfluorex.
    The European respiratory journal, 2009, Volume: 33, Issue:3

    Topics: Appetite Depressants; Cardiovascular Diseases; Diabetes Mellitus; Female; Fenfluramine; Heart Valve

2009
Contingent fees in mass tort litigation.
    Tort trial & insurance practice law journal, 2006,Fall, Volume: 42, Issue:1

    Topics: Appetite Depressants; Cardiovascular Diseases; Compensation and Redress; Fees and Charges; Fenfluram

2006
Pharmaceutical cost savings of treating obesity with weight loss medications.
    Obesity research, 1999, Volume: 7, Issue:6

    Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug

1999
Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25, Issue:10

    Topics: Animals; Brain; Cardiovascular Diseases; Fenfluramine; Male; Monoamine Oxidase; Monoamine Oxidase In

2001